Directory · IL
Biotechnology Research in Israel
A register of firms and the professionals working at them in the Biotechnology Research sector based in Israel. Browse the public index, then filter or export on Kipplo.
Companies
331 on file
Cytoreason
CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.
51 to 200 staff
Vectorbuilder
As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. VectorBuilder is the future of gene delivery. Our mission is to provide end-to-end solutions for all gene delivery needs spanning both research and therapy. We strive to offer innovative and high-quality products and services while maintaining rapid turnaround and exceptional affordability. Our “white-glove” customer care is supported by a PhD-level team with decades of collective experience to devise the best gene delivery solutions for our customers. As a result, we have received glowing customer testimonials and numerous citations in high-impact publications. Operating as a multinational company with branches in North America, Europe, China, Japan, South Korea, and Australia, VectorBuilder has served over customers from several thousand organizations worldwide, including universities, research institutions, biotech/pharma companies, and governmental agencies. So we ask you one question: Will you join us in the gene delivery revolution
501 to 1000 staff
Geneyx Genomex Ltd
Geneyx develops an AI-powered SaaS platform for clinical genetic data analysis, enabling rapid, scalable, and precise genomic interpretation for healthcare and research. The system connects directly to various sequencing devices. It automatically retrieves the sequencer output raw data, filters, analyzes, and seamlessly transforms it into a clinical diagnostic report, pinpointing the genomic variant that causes the disease. The Geneyx System serves hospitals, genetic labs, universities, and pharmaceutical companies around the world, providing tools for variant annotation, clinical reporting, and workflow automation. It integrates seamlessly with existing LIMS and EHR systems, creating a smooth, end-to-end diagnostic process.
11 to 50 staff
Quanthealth
QuantHealth is an AI company conducting patient-centric drug simulations to accelerate and de-risk drug development. Over 90% of drugs in clinical development stage fail to reach the market, which accumulates to a $45B/year direct lost to the pharma and biotech industry. Our platform allows our pharma and biotech partners to rapidly run thousands of variations of their clinical trials to optimize the trial design and significantly increase the probability of trial success, all while enabling discovery of new clinical opportunities and optimization strategies. QuantHealth has one the largest integrated datasets that spans the clinical, pharmacological and biological domains together with a proprietary AI platform that can predict patient-response to both approved and novel therapies.
51 to 200 staff
Dyn R&d
DYN R&D was founded in 2002 to fulfill the need for advanced molecular testing in the agricultural sector. Our state of the art, ISO qualified laboratory provides multiple services using DNA marker genotyping tests – specially designed to assist seed companies with marker assisted breading and purity testing, with a focus mainly on vegetable seeds. The key advantages of our DNA Marker Genotyping tests are: Accuracy- DNA marker tests are validated by breeding experts - The tests are analyzed using objective software - Our kits are manufactured through an automated process to achieve best lot to lot reproducibility. Simplicity- Tests are effective on fast and cost effective DNA extraction - Easy integration into a working molecular lab. Simple assembly of a lab based on our tests- No need for special, expensive equipment. Throughput- Genotype thousand of tests per day- Duplex markers are available: genotype 2 markers in one test- Time and cost effective.
51 to 200 staff
Gamida Cell Ltd
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Our proprietary nicotinamide (NAM) technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer. Our stem cell transplant therapy was approved by the US FDA in April 2023. Clinical study of our NK cell therapy candidate GDA-201 is ongoing.
51 to 200 staff
Biolojic Design, Ltd
Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.
51 to 200 staff
Nurexone Biologic Otcqb Nrxbf Tsxv Nrx Fse J90
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
11 to 50 staff
Protai
Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.
11 to 50 staff
Amai Proteins
Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.
11 to 50 staff
Liva Bio-Protection Technology
LiVA develops smart bio-preservation and bio-control solutions for food shelf-life extension and crop protection. Most existing solutions focus on physiological protection, rather than microbial protection; they are limited, expensive, and impose safety risks to the consumer and the environment. We offer a paradigm shift in the way we handle and consume fresh produce, by reducing the dependence on chemicals, packaging, and cold supply chain. Our technology extends shelf life by stimulating the growth of human-friendly bacteria. Instead of killing bacteria like in other solutions, we manipulate their growth. The product arrives in the form of a sachet or gel capsule containing our patent-pending blend of nutrients, which does not contain any live cultures. When added into food packs, the blend naturally and selectively stimulates the growth of good bacteria, which are naturally found in the product or its surroundings. These continue to spread at the expense of spoilage microorganisms, while the nutrient blend remains physically separated. A key feature of the technology is its ability to work at room temperature and under oxygen presence. Efficiency at room temperature would allow the storage of food products in higher temperatures where applicable. It could then lead to 30% energy saving and in turn lead to a new era in packaging design. In addition, being effective at room temperature is crucial for fruits sensitive to cold injury such as mango, and it is also crucial for fruits like berries that are temperature sensitive. Our technology is versatile and can be implemented in various industries. It can be used in processed fresh foods to reduce chemicals and improve organoleptic properties. The technology can also be used in crop protection to reduce pesticides and their antimicrobial resistance.
1 to 10 staff
Mygenes
MyGenes, headquartered in Tel Aviv, Israel and London, England, is a leading nutrigenetics and research company changing the face of the nutrition world. Founded in 2016, our mission is to help people reach a healthy weight, balance blood sugar levels, improve sports performance, reduce the risk of metabolic disease, and be healthier, all without mental confusion, without discouraging diets, and with minimal effort. MyGenes uses groundbreaking technology to provide direct access to more than 425 genetic variants and personalized genetic-based nutrition and lifestyle recommendations, tailored menus, and the genetic match percentages for thousands of foods and recipes. In 2022, MyGenes published Israel’s first-ever nutrigenetics research, revealing how individuals can overcome genetic predispositions to obesity through targeted recommendations. In 2023, MyGenes launched FoodGenes, the world’s first algorithm that assesses an individual's genetic compatibility with foods to provide personalized match scores (0-100%) and recommendations of optimal food combinations based on unique genetic findings. We are proud to have been recognized as an Israel Innovator in 2023 by Menta magazine. More information is available at mygenes.co.il.
11 to 50 staff
Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
51 to 200 staff
Eggxyt
eggXYt is developing technology to detect the gender of a chicken embryo as soon as it is laid, inside the egg and before it is incubated. We are disrupting the chicken and egg industry in the following ways: Our technology will save the lives of over chicks globally each year. Current best practice for hatcheries is to cull the male layer chicks as soon as they hatch, because they do not lay eggs and hardly have meat. Saving small chicks saves big money. By automating the separation of male and female eggs as soon as they're laid, the industry will cut incubation costs in half. The cost of manual separation will also be eliminated. Early sex separation also increases feed-to-weight ratio in the broiler and turkey industries. Over new eggs will be introduced into the market, to be used in the food, pharma and cosmetics industries.
1 to 10 staff
Ibi-Ag
IBI-Ag is an Israeli-based company addressing food protection challenges with novel biocontrol solutions. We use a novel biological active ingredient, combined with a new mode of action for developing a new class of bio-insecticides. IBI-Ag's novel biological solution for insect control allowing precise pest control of any given insect with a safe mode of action and minimal environmental traces.
1 to 10 staff
Integra Holdings Ltd
Integra Holdings is a unique venture fund that combines academic excellence, funding and R&D guidance together with a strong and proven business network — the most important elements necessary to bring academic innovation to the market. Focusing on an exclusive selection of biotech companies with proprietary solutions and a competitive advantage in their respective fields, Integra takes a hands-on approach by providing our portfolio companies the strategic planning and business development necessary to bring their technology to the market. Founded by Yissum, the Hebrew University’s technology transfer company, Integra capitalizes on the innovative applied research constantly flowing from the renowned Hebrew University of Jerusalem, Israel. Integra’s Investors: Temasek Arie Capital Invatech Holdings The first round of investment was led by Invatech, a group of private U.S. and Israeli investors Halman- Aldubi Provident and Pension Fund HUJI Fund Israeli Teachers Fund Leveraging the extensive global business network and vast experience our founders have cultivated for close to half a century, Integra is well positioned to actualize and commercialize its portfolio companies for maximum benefit.
1 to 10 staff
Minovia Therapeutics
Minovia is a clinical stage company focused on the development and application of mitochondrial cell therapies for patients suffering mitochondrial dysfunction. Mitochondrial Augmentation Technology (MAT) is a cell therapy platform where an off-the-shelf allogeneic isolated mitochondria are developed as cryopreserved, healthy and functional, energy producing organelles and used to augment various cell types to be used as therapeutics products. The lead product, MNV-201 consists of autologous hematopoietic stem and progenitor cells (HSPCs) augmented ex vivo with healthy mitochondria. MNV-201 is currently in clinical trial for Pearson Syndrome and in Pre-clinical stage for Myelodysplastic Syndrome (MDS) indicating encouraging clinical and pre-clinical proof-of-concept for both primary mitochondrial diseases and age-related bone marrow failures. In Minovia we developed novel mitochondria-based biomarkers that allows us to stratify patients according to their "MitoScore". Minovia is establishing a novel aspect of cell therapy quality focusing on mitochondrial science, developing robust analytical methods to measure cellular mitochondrial function, as well as modalities to rescue mitochondrial dysfunction in different cell therapies.
11 to 50 staff
Pangea Biomed
Pangea is redefining precision oncology and increasing the number of patients who can benefit from it. Immunotherapy and precision oncology have been around for decades, providing hope for those with cancer, but less than 10 percent of cancer patients benefit from today’s treatments. By coupling the hidden power of RNA sequencing with ML-enabled network effects, our ENLIGHT platform can surface relevant biological insights to pinpoint the best path forward toward combating a patient’s cancer.
11 to 50 staff
Accellta Ltd
Imagine a world where stem cell therapies are no longer a distant dream, but an accessible reality. Accellta isn't just developing cutting-edge stem cell manufacturing solutions; we're propelling the entire regenerative medicine industry forward, one collaborative partnership at a time, Accellta's revolutionary 3D suspension technology unlocks the true potential of stem cells. Our proprietary platform slashes manufacturing costs by over 90% and speeds up production by 65%, just pure, potent stem cells expanding and differentiating continuously, robustly, and affordably within dynamic bioreactors. This isn't just science fiction; it's the future of healing. Accellta's technology empowers researchers and developers to create: for treating chronic diseases, injuries, and even organ failure- for personalized medicine and drug testing- for revolutionizing drug discovery, for the food-tech industry. We're a passionate team of scientists and entrepreneurs driven by the belief that stem cell therapies hold the key to unlocking a healthier world. Join us on this incredible journey as we transform the impossible into the everyday.
11 to 50 staff
Embryonics
Embryonics is bringing novel artificial intelligence (AI) solutions to the world of IVF. Despite the market increasing steadily, success rates have disappointingly plateaued (~30%.) Taking a holistic approach, we are committed to addressing the reasons behind this with our team of expert computer engineers, medics and biologists. We design deep learning neural networks to improve embryo selection, genetic analysis and patient schematics, utilizing Big Data to service those in need. By improving and simplifying the process we hope to make IVF safer, cheaper, more accessible and above all more successful. In short, we aim to bring reproductive autonomy to parents in need, delivering them their next generation.
11 to 50 staff
Everads Therapy Ltd
Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.
1 to 10 staff
Kahr-Medical Ltd
KAHR Medical is developing an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications
11 to 50 staff
Mirror Biologics, Ltd
Wholly-owned subsidiary Mirror Biologics, Inc. conducts GMP manufacturing and related research and development.
11 to 50 staff
Peel Therapeutics
Over the course of millions of years, nature evolved to create the world’s most awe-inspiring, life-changing health outcomes. Peel Therapeutics translates these evolutionary outliers to develop medicines for patients with cancer and inflammatory diseases. Using scientific and medical expertise, state-of-the-art technology and drug development knowledge, we redesign what nature offers into medicines for patients by tackling solubility, scalability, and bioavailability. Our clinical stage therapeutic pipeline treats a spectrum of devastating conditions, with a near-term focus on cancer and inflammation. At Peel Therapeutics, we push the limits of biology to develop highly effective and safe medicines for patients that transcend the incremental.
11 to 50 staff
